- Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
-
Lye Yl, Shan B, Jia Ch, Liu J, Hou J, Du Wl, Feng R, Liang P
- KMID: 2542751
- Ann Dermatol.
- 2023 May;35(Suppl1):S100-S102.
- doi: 10.5021/ad.21.072
Sintilimab is an anti-programmed cell death receptor-1 antibody. The phase III clinical trial ORIENT-12 confirmed the safety of sintilimab combined with pemetrexed/platinum in the treatment of advanced squamous non-small cell... -
- CITED
-
- Close
- SHARE
-
- Close
